ChromoCure, Inc. (KKUR)
ChromoCure, Inc. operates in the Medical - Specialties industry of the Healthcare sector, headquartered in Reno, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $8,200. Its beta of -0.07 implies it has historically moved less than the broad market.
ChromoCure, Inc. specializes in designing and delivering exclusive systems for cancer identification. Their primary offering, the Chromosomal Scanner Series 200, is a detection system capable of identifying a distinct genomic characteristic that is universally present in all cancers yet entirely absent in healthy cells. Furthermore, the company dedicates its scientific and technological expertise to investigating non-toxic and non-invasive strategies for both cancer treatment and cure research. Established in 2001 and based in Reno, Nevada, the organization rebranded as ChromoCure, Inc. in June 2009, having previously been known as Cyberhand Technologies International, Inc.
ChromoCure, Inc. is most often compared with the following Healthcare names: